LitCovid-sample-Enju  

PMC:7199903 / 586-903 JSONTXT 14 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T85 5-6 -COMMA- denotes ,
T86 7-10 CC denotes and
T87 11-21 VBD denotes determined
T88 22-25 DT denotes the
T89 26-37 NN denotes composition
T90 38-40 IN denotes of
T91 41-44 DT denotes the
T92 45-51 NN denotes glycan
T93 52-57 NNS denotes sites
T94 58-60 IN denotes by
T95 61-65 NN denotes mass
T96 66-78 NN denotes spectrometry
T97 80-83 DT denotes The
T98 84-92 NN denotes analysis
T99 93-101 VBZ denotes provides
T100 102-103 DT denotes a
T101 104-113 NN denotes benchmark
T102 114-118 WDT denotes that
T103 119-122 MD denotes can
T104 123-125 VB denotes be
T105 126-130 VBN denotes used
T106 131-133 TO denotes to
T107 134-141 VB denotes measure
T108 142-149 NN denotes antigen
T109 150-157 NN denotes quality
T110 158-160 IN denotes as
T111 161-169 NNS denotes vaccines
T112 170-173 CC denotes and
T113 174-182 NN denotes antibody
T114 183-188 NNS denotes tests
T115 189-192 VBP denotes are
T116 193-202 VBN denotes developed
T117 204-211 NN denotes Science
T118 212-216 DT denotes this
T119 217-222 NN denotes issue
T120 223-224 NN denotes p
T121 226-229 CD denotes 330
T122 231-232 DT denotes A
T123 233-237 NN denotes mass
T124 238-250 NN denotes spectrometry
T125 251-259 NN denotes analysis
T126 260-267 VBZ denotes reveals
T127 268-271 DT denotes the
T128 272-278 NN denotes glycan
T129 279-290 NN denotes composition
T130 291-293 IN denotes at
T131 294-297 DT denotes all
T132 298-311 NN denotes glycosylation
T133 312-317 NNS denotes sites
R100 T98 T97 arg1Of analysis,The
R101 T98 T99 arg1Of analysis,provides
R102 T101 T99 arg2Of benchmark,provides
R103 T101 T100 arg1Of benchmark,a
R104 T101 T102 arg1Of benchmark,that
R105 T101 T103 arg1Of benchmark,can
R106 T105 T103 arg2Of used,can
R107 T101 T104 arg1Of benchmark,be
R108 T105 T104 arg2Of used,be
R109 T101 T105 arg2Of benchmark,used
R110 T107 T105 arg3Of measure,used
R111 T107 T106 arg1Of measure,to
R112 T101 T107 arg1Of benchmark,measure
R113 T109 T107 arg2Of quality,measure
R114 T109 T108 arg1Of quality,antigen
R115 T107 T110 arg1Of measure,as
R116 T116 T110 arg2Of developed,as
R117 T111 T112 arg1Of vaccines,and
R118 T114 T112 arg2Of tests,and
R119 T114 T113 arg1Of tests,antibody
R120 T112 T115 arg1Of and,are
R121 T116 T115 arg2Of developed,are
R122 T112 T116 arg2Of and,developed
R123 T120 T117 arg1Of p,Science
R124 T120 T118 arg1Of p,this
R125 T120 T119 arg1Of p,issue
R126 T125 T122 arg1Of analysis,A
R127 T125 T123 arg1Of analysis,mass
R128 T125 T124 arg1Of analysis,spectrometry
R129 T125 T126 arg1Of analysis,reveals
R130 T129 T126 arg2Of composition,reveals
R131 T129 T127 arg1Of composition,the
R132 T129 T128 arg1Of composition,glycan
R133 T129 T130 arg1Of composition,at
R134 T133 T130 arg2Of sites,at
R135 T133 T131 arg1Of sites,all
R136 T133 T132 arg1Of sites,glycosylation
R87 T86 T85 arg1Of and,","
R89 T87 T86 arg2Of determined,and
R91 T89 T87 arg2Of composition,determined
R92 T89 T88 arg1Of composition,the
R93 T89 T90 arg1Of composition,of
R94 T93 T90 arg2Of sites,of
R95 T93 T91 arg1Of sites,the
R96 T93 T92 arg1Of sites,glycan
R97 T89 T94 arg1Of composition,by
R98 T96 T94 arg2Of spectrometry,by
R99 T96 T95 arg1Of spectrometry,mass